Description
Verify COA Lab Results:
https://portal.ils-lab.com/verify/j7pJPvehSMfUA0NW
Product Overview: Retatrutide (LY3437943)
Retatrutide (LY3437943) is a single 39-amino acid synthetic peptide engineered as a triple agonist (tri-agonist) targeting the Glucose-Dependent Insulinotropic Polypeptide (GIP), Glucagon-Like Peptide-1 (GLP-1), and Glucagon (GCG) receptors. Modified with a C20 fatty diacid chain for high-affinity plasma albumin binding, Retatrutide exhibits an extended plasma half-life of approximately 6 days. By combining incretin action with direct glucagon receptor-mediated energy expenditure, Retatrutide represents a landmark compound for studying multi-receptor metabolic regulation, profound body weight reduction, and hepatic fat clearance.
Primary Research Applications & Reasons for Study
- Triple GIP/GLP-1/Glucagon Co-Agonism: Examining the multi-pathway mechanics of simultaneous GIP, GLP-1, and GCG receptor stimulation over mono- and dual-agonist compounds.
- Glucagon-Mediated Thermogenesis & Lipolysis: Upregulating hepatic lipid metabolism and basal metabolic rate directly through glucagon receptor signaling without causing hyperglycemia.
- Hepatic Steatosis Clearance: Evaluating rapid mobilization and clearance of intrahepatic lipid accumulation in non-alcoholic fatty liver disease (NAFLD/MASH) models.
- Central Appetite & Energy Expenditure Balance: Assessing hypothalamic satiety signaling alongside increased caloric expenditure in diet-induced obesity assays.
Expected Research Results & Timeline Metrics
- Phase 1 / Hours 1–24
Immediate Incretin Response & Thermogenic Onset: Rapid glucose-dependent insulin release, acute postprandial blood sugar attenuation, and immediate upregulation of hepatic oxygen consumption. - Phase 2 / Weeks 1–4
Accelerated Fat Oxidation & Glycemic Control: Statistically significant reduction in daily feed intake, marked improvements in insulin sensitivity parameters, and early reductions in visceral fat mass. - Phase 3 / Weeks 12–24+
Unprecedented Adiposity Loss & Liver Fat Reduction: Up to ~24%+ total body weight reduction in experimental obesity models, accompanied by complete resolution of hepatic steatosis in metabolic research protocols.
Key Research Benefits
- First-in-Class Triple Agonism: Combines appetite control (GLP-1), metabolic buffering/nutrient handling (GIP), and active caloric burning (Glucagon) into one molecule.
- Direct Metabolic Rate Elevation: Glucagon receptor activation drives energy expenditure directly, overcoming the adaptive thermogenesis plateau common in calorie-restricted models.
- Extended Half-Life Structure: C20 fatty acid modification provides exceptional plasma stability for extended multi-day experimental protocols.
- Frontier Metabolic Tool: Serves as the premier benchmark compound for cutting-edge studies in extreme obesity, metabolic syndrome, and fatty liver disease.
THIS PRODUCT IS INTENDED SOLELY FOR IN VITRO LABORATORY RESEARCH AND EXPERIMENTAL PURPOSES. It is strictly prohibited for human consumption, clinical trials, therapeutic administration, cosmetic use, or veterinary application. This product is not an FDA-approved drug, medical food, or dietary supplement. It is not intended to diagnose, treat, cure, or prevent any disease, illness, or medical condition. Any handling, reconstitution, or experimentation involving this chemical compound must be conducted strictly by qualified, trained laboratory professionals utilizing appropriate containment and personal protective equipment in accordance with scientific biosafety standards. Buyers and users assume full liability for compliance with local, state, and federal laws regarding the handling and possession of research compounds.